Akebia's Vafseo Shows Safety Edge Over ESAs in VOICE Trial
Event summary
- Akebia and USRC halted the VOICE trial early after interim data showed Vafseo reduced hospitalizations vs. ESAs in dialysis patients.
- Primary endpoint met with a win odds of 1.16 (p=0.0016), demonstrating statistical superiority.
- Vafseo's TIW dosing regimen replicated safety outcomes from prior INNO2VATE trials.
- Results to be submitted for presentation at an upcoming scientific meeting.
The big picture
Akebia’s positive VOICE trial data reinforces the potential of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) to challenge erythropoiesis-stimulating agents (ESAs) in dialysis anemia. The results could accelerate Vafseo's adoption, particularly as the only oral HIF-PHI available in the U.S., though long-term safety and cost-effectiveness will remain key considerations for payers and clinicians.
What we're watching
- Regulatory Impact
- Whether the VOICE trial results will influence broader adoption of Vafseo in dialysis anemia treatment.
- Market Differentiation
- How Akebia positions Vafseo against existing ESAs given the safety data advantage.
- Commercialization Strategy
- The pace at which Akebia can expand Vafseo's market reach beyond current approvals.